This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Implied Volatility Surging for Cidara Therapeutics (CDTX) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Cidara Therapeutics (CDTX) stock based on the movements in the options market lately.
Cidara Therapeutics (CDTX) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Cidara Therapeutics (CDTX) delivered earnings and revenue surprises of 0.00% and 95.74%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Cidara Therapeutics (CDTX) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
by Zacks Equity Research
Cidara Therapeutics (CDTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cidara Therapeutics (CDTX) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Cidara Therapeutics (CDTX) delivered earnings and revenue surprises of 166.67% and 415.09%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Cidara Therapeutics (CDTX) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
by Zacks Equity Research
Cidara Therapeutics (CDTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cidara Therapeutics (CDTX) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Cidara Therapeutics (CDTX) delivered earnings and revenue surprises of -129.41% and -83.95%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Cidara Therapeutics (CDTX) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
by Zacks Equity Research
Cidara Therapeutics (CDTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
New Strong Sell Stocks for March 5th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today
Cidara Therapeutics (CDTX) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Cidara Therapeutics (CDTX) delivered earnings and revenue surprises of 14.58% and -32.14%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Cidara Therapeutics (CDTX) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Cidara Therapeutics (CDTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cidara Therapeutics (CDTX) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Cidara Therapeutics (CDTX) delivered earnings and revenue surprises of -87.50% and -79.00%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Cidara Therapeutics (CDTX) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Cidara Therapeutics (CDTX) delivered earnings and revenue surprises of -35.29% and -49.40%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
What Makes Cidara Therapeutics (CDTX) a New Strong Buy Stock
by Zacks Equity Research
Cidara Therapeutics (CDTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
What Makes Cidara Therapeutics (CDTX) a New Buy Stock
by Zacks Equity Research
Cidara Therapeutics (CDTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Cidara Therapeutics (CDTX) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Cidara Therapeutics (CDTX) delivered earnings and revenue surprises of -44.83% and -83.35%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Cidara Therapeutics (CDTX) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Cidara Therapeutics (CDTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
New Strong Sell Stocks for January 16th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today
What Makes Cidara Therapeutics (CDTX) a New Buy Stock
by Zacks Equity Research
Cidara Therapeutics (CDTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Cidara Therapeutics (CDTX) Enters Oversold Territory
by Zacks Equity Research
Cidara Therapeutics has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
Cidara Therapeutics Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Cidara Therapeutics has been struggling lately, but the selling pressure may be coming to an end soon.
Options Traders Expect Huge Moves in Cidara Therapeutics (CDTX) Stock
by Zacks Equity Research
Surging implied volatility makes Cidara Therapeutics (CDTX) stock lucrative to the option traders.
5 Biotech Stocks Well Poised to Surpass Expectations in Q3
by Zacks Equity Research
The pharma and biotech industry has demonstrated strength
What's in the Cards for Merrimack (MACK) in Q3 Earnings?
by Zacks Equity Research
Merrimack Pharmaceuticals (MACK) will report its third-quarter results later this month. Investors focus is expected to be on pipeline updates.
What's in the Cards for Repros (RPRX) This Earnings Season?
by Zacks Equity Research
Repros Therapeutics (RPRX) will report its third-quarter results later this month. Investors focus is expected to be on pipeline updates.
Is a Surprise Coming for Cidara Therapeutics (CDTX) This Earnings Season?
by Zacks Equity Research
Cidara Therapeutics (CDTX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into this earnings season.